title: Defining cases of severe pediatric diarrhea for an efficacy trial of an enterotoxigenic Escherichia coli (ETEC) vaccine: Report on an international workshop, Washington DC, March 2016.
abstract: Enterotoxigenic Escherichia coli (ETEC) causes severe acute watery diarrhea. No ETEC vaccine is available but candidates are in development, including ETVAX, an oral, whole-cell inactivated vaccine. ETVAX is being tested in a descending-age trial in Bangladesh. If found safe and immunogenic, investigators may test it for efficacy in children. Like oral rotavirus vaccines, we expect that ETVAX will be most effective at decreasing the incidence of moderate-to-severe ETEC episodes. Thus, for an efficacy trial outcome, it will be necessary to triage patients into moderate-to-severe versus mild disease. A severity scale specific to ETEC does not exist. To develop this scale, PATH convened a committee of international experts for a two-day meeting to strategize on diagnostic scale development. The workshop began with four presentations. The first described existing scales, item selection, and issues related to validation, reliability, and ease of use. The other three presentations provided details on the following published scores: the DHAKA score, validated for use with Bangladeshi children seeking diarrhea treatment; a modified-Vesikari score for evaluating North American outpatient children with diarrhea; and the Community Diarrhea Assessment (CODA) score developed for passive-case surveillance of Peruvian children with diarrhea. Following the presentations and discussion, the committee made several recommendations including: modifying existing scores to make them ETEC-centric; evaluating scoring systems against an objective measure of dehydration (i.e., the percent change in a child's bodyweight following rehydration); and adding an item to the scale measuring ETEC effects on growth faltering. The committee also discussed using available data sets to evaluate scores, but was concerned that if investigators characterized patients using different procedures than prescribed by the score, the results would be difficult to interpret. Committee members suggested new data collection and recommended conducting studies in Sub-Saharan Africa. The study results would be presented for peer-review and to regulatory authorities.
authors.affiliation: PATH, 455 Massachusetts Ave. NW, Washington, DC 2001-2621, USA. Electronic address: twierzba@path.org.
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Wierzba
authors.affiliation: PATH, 455 Massachusetts Ave. NW, Washington, DC 2001-2621, USA. Electronic address: abourgis@path.org.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Bourgis
authors.affiliation: PATH, 455 Massachusetts Ave. NW, Washington, DC 2001-2621, USA.
mesh_terms: D003967:Diarrhea / Q000175:diagnosis / Q000473:pathology* / Q000517:prevention & control*; D004493:Education; D054307:Enterotoxigenic Escherichia coli / Q000276:immunology*; D004927:Escherichia coli Infections / Q000175:diagnosis / Q000473:pathology* / Q000517:prevention & control*; D022361:Escherichia coli Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D012720:Severity of Illness Index; D014861:Washington
chemical_list: D022361:Escherichia coli Vaccines
keywords: Diarrhea; ETEC; Score; Severity; Vaccines